|
Delayed
London S.E.
07:27:23 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 0.1396 GBX | -0.29% |
|
+3.41% | -45.25% |
| 09-22 | WINNERS & LOSERS: Petro Matad sinks on PetroChina blow; Midwich up | AN |
| 09-14 | WINNERS & LOSERS: Tribal to sell assets; Brave Bison ups System1 tilt | AN |
| Market Cap | 3.78M 5M 4.44M 4.15M 7.12M 481M 7.22M 50.24M 19.45M 245M 18.77M 18.36M 787M | P/E 2024 |
-0.13x | P/E 2025 | -5.88x |
|---|---|---|---|---|---|
| Enterprise Value | 3.69M 4.87M 4.33M 4.05M 6.94M 469M 7.04M 48.94M 18.95M 239M 18.29M 17.89M 767M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
94.63% | Yield 2024 * |
-
| Yield 2025 | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| LVRT | Delayed | |
Deutsche Boerse AG
| 1RT | Delayed | |
|
Börse Stuttgart
| 1RT | Delayed |
| 25-05-23 | Nuformix : Prospectus | PU |
| 23-10-05 | Nuformix to fund its unlicensed programs with NXP001 windfall | AQ |
| 22-12-20 | Nuformix hoping to "initiate discussions with major pharma" in 2023 | AQ |
| 22-12-20 | Nuformix hoping to 'initiate discussions with major pharma' in 2023 | EQ |
| 20-02-18 | Nuformix : Appointment of Dr Karl Keegan | PU |
| 1 day | -0.29% | ||
| 1 week | +3.41% | ||
| Current month | -3.72% | ||
| 1 month | -15.39% | ||
| 3 months | -22.44% | ||
| 6 months | -20.23% | ||
| Current year | -45.25% |
| 1 week | 0.13 |  | 0.16 |
| 1 month | 0.13 | | 0.17 |
| Current year | 0.12 | | 0.4 |
| 1 year | 0.12 | | 0.56 |
| 3 years | 0.04 | | 0.56 |
| 5 years | 0.04 | | 1.93 |
| 10 years | 0.04 | | 14.89 |
| Manager | Title | Age | Since |
|---|---|---|---|
Shaun Zulafqar
SEC | Corporate Secretary | - | 2025-04-28 |
| Director | Title | Age | Since |
|---|---|---|---|
Daniel Gooding
BRD | Director/Board Member | 53 | 2022-06-30 |
| Director/Board Member | 61 | 2020-12-01 | |
Timothy Metcalfe
CHM | Chairman | 54 | 2026-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 11/5/24 | Free | Director | 22,000,000 | 2.6852% | ||
| 11/5/24 | Free | Chairman | 22,000,000 | 2.6852% | ||
| 11/5/24 | Free | Founder | 12,000,000 | 1.4646% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.29% | +3.41% | -40.60% | -45.25% | 4.83M | |
| -0.62% | -2.71% | +39.30% | +114.07% | 1,025B | |
| -2.30% | -4.44% | +39.03% | +66.07% | 623B | |
| -0.63% | -1.96% | +6.36% | +74.38% | 459B | |
| -1.03% | -2.82% | +59.56% | +39.69% | 355B | |
| -0.27% | -3.39% | +22.44% | +40.33% | 336B | |
| -0.47% | -1.89% | +13.00% | +25.89% | 270B | |
| +0.18% | -4.02% | -3.26% | +10.03% | 247B | |
| -3.38% | +0.30% | +36.44% | +51.54% | 220B | |
| -1.04% | -1.46% | +32.70% | +96.82% | 183B | |
| Average | -0.10% | -0.85% | +20.50% | +47.36% | 371.82B | |
| Weighted average by Cap. | +0.19% | -2.11% | +30.37% | +69.50% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -3.64M -4.81M -4.27M -4M -6.86M -463M -6.95M -48.34M -18.71M -236M -18.06M -17.67M -758M | -653K -862K -766K -716K -1.23M -83.01M -1.25M -8.66M -3.35M -42.28M -3.24M -3.17M -136M |
| Net Debt | -20.21K -26.7K -23.72K -22.18K -38.05K -2.57M -38.57K -268K -104K -1.31M -100K -98.07K -4.21M | -97.55K -129K -114K -107K -184K -12.41M -186K -1.3M -501K -6.32M -484K -473K -20.3M |
Employees
3
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-02 | GBX 0.1396 | -0.29% | 4,521,332 |
| 26-10-01 | GBX 0.1400 | -3.45% | 12,038,657 |
| 26-09-30 | GBX 0.1450 | 0.00% | 8,284,490 |
| 26-09-29 | GBX 0.1450 | -3.33% | 12,627,080 |
| 26-09-28 | GBX 0.1500 | +11.11% | 72,855,027 |
- Stock Market
- Stocks
- LVRT Stock
Select your edition
All financial news and data tailored to specific country editions
